News | Heart Failure | October 05, 2020

ACC and Novartis Collaborate to Optimize Heart Failure Care With TRANSFORM Study

Study will examine a redesigned outpatient experience to improve guideline-directed care for heart failure patients

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

October 5, 2020 — The American College of Cardiology (ACC) says heart failure (HF) is a cardiovascular epidemic. In addition to being increasingly prevalent, HF patients often have poor outcomes after initial diagnosis and poor quality of life. The ACC has committed to transforming cardiovascular care for these patients through a collaboration with Novartis on TRANSFORM HFrEF, a national study aiming to improve care and outcomes for millions of heart failure patients.

“Heart Failure is the No. 1 diagnosis leading to potentially preventable hospitalizations, especially among the elderly,” said ACC Interim CEO Cathleen Gates. “Advancing quality, equity and value of cardiovascular care is a strategic priority for the College, and programs like this help us to optimize HF patient treatment and care and outcomes.” 

The goal of TRANSFORM HFrEF will be to study the current landscape of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) and determine effective methods and models of increasing adherence to GDMT and quality of life in outpatient settings. This six-month randomized registry trial will aim to optimize GDMT and enhance patient engagement through redesigning the 20-minute outpatient appointment with interventions directed both to patient and caregiver. The trial will assess optimization of GDMT and improvements in patient-reported outcomes compared with usual care. 

Although clinical practice guidelines clearly articulate optimal GDMT for care of patients with HFrEF, implementation of GDMT into the management of such patients has proven to be suboptimal, with most patients under-treated relative to goal therapy. Understanding reasons for pervasive gaps in GDMT is important to make strides to improve utilization of life-saving therapies for patients with HFrEF.

“The reasons for inadequate GDMT use may include clinician-based factors or patient-related factors, said James L. Januzzi, M.D., FACC, primary investigator for the trial and ACC Board of Trustees member. “Often times in the 20-minute office visit the clinician has numerous issues to consider and patients may not fully understand the impact of their treatment, resulting in less than optimal GDMT, which impacts physical health of the patient and ultimately quality of life.”

This research will leverage the PINNACLE Registry operated by Veradigm in association with the ACC, one of the largest outpatient cardiovascular clinical data registries in the world. It will provide tools that shift standard clinical interview and documentation requirements outside the doctor’s appointment and provide innovative tools to build the patient and physician relationship through trust and shared goal setting.

“It is our hope that the insights and results gained from this research will advance HF care and create a new standard for effective approaches to increasing adherence and improving outcomes for heart failure patients,” said David Platt, M.D., VP, Medical Unit Head, Cardiovascular, Renal & Metabolism, Novartis.

This initiative is the latest under the TRANSFORM umbrella. ACC introduced TRANSFORM as a new kind of quality research program aimed to improve health care by transforming the quality of care across the multi-faceted areas of cardiovascular disease. TRANSFORM programs leverage clinical registry data, office-based interventions, and partnerships to include the pharmaceutical and medical device industry, health plans, employers, clinicians and patients. 

Related ACC PINNACLE Registry Content:

American College of Cardiology Research Network Uses Big Data to Connect Practices With Trials

Aspirin May be Inappropriately Prescribed to 10 Percent of Heart Patients

Study Reveals Low Statin Use in Diabetics Despite Cardioprotective Effects, Guidelines

American College of Cardiology Launches PINNACLE-AF Outpatient Registry
 

Related Content

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiolog...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a